SHANGHAI, April 16, 2023 /PRNewswire/ — Abbisko (Stock Code: 2256.HK) announced the results of five latest preclinical studies at the 2023 American Association for Cancer Research (AACR) annual meeting. These include its self-developed CSF-1R inhibitor Pimicotinib (ABSK021), which has…